Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
ESMO Open
|
July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with <i>ALK</i>-positive, crizotinib-resistant, non-small cell lung cancer
Sai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.
Heliyon
|
May 3, 2024
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss
David J H Bian, Anna-Maria Lazaratos, Sarah M Maritan, et al.
Quality Management in Health Care
|
October 11, 2023
Choosing Wisely and Promoting High-Value Care and Staff Safety During the COVID-19 Pandemic in a Large Safety Net System
Mona Krouss, Sigal Israilov, Nessreen Mestari, et al.
The American Journal of Cardiology
|
March 5, 2011
Early detection and prediction of cardiotoxicity in chemotherapy-treated patients
Heloisa Sawaya, Igal A Sebag, Juan Carlos Plana, et al.
Molecular Cancer Therapeutics
|
June 28, 2019
Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Mathilde Couëtoux du Tertre, Maud Marques, Lise Tremblay, et al.
Clinical Chemistry
|
July 30, 2015
Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab
Mary Putt, Virginia Shalkey Hahn, James L Januzzi, et al.
Circulation. Cardiovascular Imaging
|
June 30, 2012
Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab
Heloisa Sawaya, Igal A Sebag, Juan Carlos Plana, et al.
Journal of the American College of Cardiology
|
December 3, 2013
Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab
Bonnie Ky, Mary Putt, Heloisa Sawaya, et al.
Therapeutic Advances in Medical Oncology
|
August 4, 2022
The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer
Doreen A Ezeife, Eldon Spackman, Rosalyn A Juergens, et al.
Clinical Proteomics
|
February 15, 2020
Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition
Mathilde Couëtoux du Tertre, Maud Marques, Suzan McNamara, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
ESMO Open
|
July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with <i>ALK</i>-positive, crizotinib-resistant, non-small cell lung cancer
Sai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.
Heliyon
|
May 3, 2024
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss
David J H Bian, Anna-Maria Lazaratos, Sarah M Maritan, et al.
Quality Management in Health Care
|
October 11, 2023
Choosing Wisely and Promoting High-Value Care and Staff Safety During the COVID-19 Pandemic in a Large Safety Net System
Mona Krouss, Sigal Israilov, Nessreen Mestari, et al.
The American Journal of Cardiology
|
March 5, 2011
Early detection and prediction of cardiotoxicity in chemotherapy-treated patients
Heloisa Sawaya, Igal A Sebag, Juan Carlos Plana, et al.
Molecular Cancer Therapeutics
|
June 28, 2019
Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Mathilde Couëtoux du Tertre, Maud Marques, Lise Tremblay, et al.
Clinical Chemistry
|
July 30, 2015
Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab
Mary Putt, Virginia Shalkey Hahn, James L Januzzi, et al.
Circulation. Cardiovascular Imaging
|
June 30, 2012
Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab
Heloisa Sawaya, Igal A Sebag, Juan Carlos Plana, et al.
Journal of the American College of Cardiology
|
December 3, 2013
Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab
Bonnie Ky, Mary Putt, Heloisa Sawaya, et al.
Therapeutic Advances in Medical Oncology
|
August 4, 2022
The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer
Doreen A Ezeife, Eldon Spackman, Rosalyn A Juergens, et al.
Clinical Proteomics
|
February 15, 2020
Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition
Mathilde Couëtoux du Tertre, Maud Marques, Suzan McNamara, et al.
Page
of 7